Cell immunotherapy through dendritic cells (DC) presents a hopeful strategy for the treatment of various tumors. The aim of our study was to find which progenitor cells are most suitable for the preparation of dendritic cells in acute lymphoblastic leukemia (ALL) in pediatric patients, whether blasts from bone marrow or dendritic cells generated from peripheral blood mononuclear cells taken at the time of remission after induction chemotherapy. DC generated from the BM blasts of patients with B-ALL and T-ALL (n = 15) at the time of diagnosis expressed low levels of costimulatory molecules and CD markers typical for mature DC. In contrast, DC cultivated from peripheral mononuclear cells of patients (n = 9) had comparable morphology and expression of costimulatory molecules to DC obtained from healthy individuals, which was even higher after tumor lysate pulsing. Autologous lymphocyte proliferation increased after DC blasts lysate pulsation and further after lymphocyte restimulation, showing evidence of induction of specific cytotoxic lymphocytes. When comparing both cell sources for the preparation of DC in patients with ALL, it appears that peripheral mononuclear cells obtained after chemotherapy are more suitable than bone marrow leukemic blasts due to similar morphology, phenotypic, and functional capacity to monocytes of healthy donors. Despite this, it is necessary to take into account individual variability when preparing DC-based vaccines. The final verification of the efficiency of immunotherapy against residual hematopoietic malignant cells in patients with ALL can only be obtained through a clinical study.

Institute of Immunology Charles University 2nd Medical Faculty and Faculty Hospital Motol Prague Czech Republic

Zobrazit více v PubMed

Blood. 1999 Nov 15;94(10):3531-40 PubMed

J Immunother. 2000 Jul-Aug;23(4):487-98 PubMed

Br J Haematol. 1993 Mar;83(3):412-8 PubMed

Br J Haematol. 2001 Dec;115(4):831-44 PubMed

J Exp Med. 1996 Jan 1;183(1):283-7 PubMed

Blood. 1997 Feb 15;89(4):1133-42 PubMed

Oncol Rep. 1999 Sep-Oct;6(5):1057-63 PubMed

J Immunol. 2000 Mar 1;164(5):2487-95 PubMed

J Urol. 1999 Mar;161(3):777-82 PubMed

Int Immunol. 2002 Jul;14(7):741-50 PubMed

Blood. 2001 May 1;97(9):2764-71 PubMed

Nat Med. 1996 Jan;2(1):52-8 PubMed

Cancer Immunol Immunother. 2001 Oct;50(8):417-27 PubMed

Crit Rev Immunol. 1998;18(1-2):65-75 PubMed

Cancer Res. 2002 May 15;62(10):2861-8 PubMed

Blood. 1999 Sep 15;94(6):2048-55 PubMed

Prostate. 1999 Apr 1;39(1):54-9 PubMed

Leukemia. 2001 Feb;15(2):278-9 PubMed

Blood. 1999 Feb 1;93(3):780-6 PubMed

Eur J Haematol. 2003 May;70(5):333-45 PubMed

N Engl J Med. 1995 Jun 15;332(24):1618-30 PubMed

Cancer Immunol Immunother. 2002 Apr;51(2):72-8 PubMed

Leuk Res. 2002 Feb;26(2):191-201 PubMed

Expert Opin Biol Ther. 2002 Jan;2(1):35-43 PubMed

Adv Cancer Res. 1992;59:245-322 PubMed

J Exp Med. 1988 Oct 1;168(4):1247-53 PubMed

Nat Med. 1998 Mar;4(3):328-32 PubMed

Exp Hematol. 1995 Oct;23(11):1148-51 PubMed